OROX BioSciences, Inc.

OROX BioSciences, Inc. is an early stage biotechnology start-up dedicated to efficient discovery and development of innovative small molecule drugs to address unmet medical needs for cancer and fibrotic diseases since 2017.

Our core technology is around inhibition of soluble epoxide hydrolase (sEH) to ameliorate disease states. The core competence of our team is in understanding lipid metabolism and its interphase with disease states.

A key distinguishing feature of our team is having the world’s foremost authority in the field of sEH research, Dr. Bruce D. Hammock, who is a Distinguished professor at UC-Davis and discoverer of soluble epoxide hydrolase (sEH) and its biomedical relevance as our Chairman of the Scientific Advisory Board (SAB). Dr. Hammock is a member of the National Academy of Sciences and the National Academy of Inventors, has published over 1200 peer reviewed manuscripts, and has founded several companies. Our SAB includes several distinguished academics and physicians. Also, we are strengthened by presence of Dr. Gregory Reyes as our COO and CMO with over 30 years of biotech/large pharma leadership experience spanning multiple therapeutic areas. His teams have nominated and progressed over 50 compounds, both small molecules and biologics, from discovery into preclinical and clinical development. Finally, Dr. Mehran F. Moghaddam, who serves as the CEO and Chairman of the Board, has accumulated his small molecule and biologics discovery and development experience from DuPont, Pfizer, and Celgene since 1995. He is well versed in the area of sEH as he completed his post-doctoral training in that area in Dr. Hammock’s lab. Dr. Moghaddam holds an executive MBA from University of Southern California.